Inhibrx Biosciences, Inc. (INBX) Stock Price & Analysis
Inhibrx Biosciences, Inc. (INBX) fell 4.06% to USD 81.55 as of July 25, 2026 at 04:58 UTC, according to Nexqual real-time market data.
INBX last closed at USD 85; the session ranged USD 81.54–86 on volume of 164,051 shares. Market capitalization is $1.20B, with a 52-week range of USD 20.55–155.29 (NMS). Source: Nexqual, July 25, 2026 at 04:58 UTC.
Key Statistics (as of July 25, 2026 at 04:58 UTC)
| Price | USD 81.55 |
|---|---|
| Change | ▼ 4.06% (down) |
| Previous Close | USD 85 |
| Open | USD 86 |
| Day Range | USD 81.54 – 86 |
| 52-Week Range | USD 20.55 – 155.29 |
| Volume | 164,051 shares |
| Market Cap | $1.20B |
| Exchange | NMS |
Technical Analysis (INBX)
Nexqual's technical model rates INBX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:58 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.54 (neutral) |
| vs SMA50 | Below (USD 96.3) |
| MACD | -3.44 (negative) |
Analyst Ratings (INBX)
Wall Street analysts rate INBX "None" based on 2 analysts, with a mean price target of USD 277.5 (range USD 230–325), per Nexqual as of July 25, 2026 at 04:58 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 277.5 |
| High Target | USD 325 |
| Low Target | USD 230 |
| Buy / Hold / Sell | 2 / 1 / 0 |
Earnings (INBX)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -2.28 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -2.15 vs est -1.2 ▼ miss |
| 2025-12-31 | USD -2.11 vs est -2.08 ▼ miss |
| 2025-09-30 | USD -2.28 vs est -1.72 ▼ miss |
| 2025-06-30 | USD -1.85 vs est -2.6 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:58 UTC.
Financials & Fundamentals (INBX)
| Total Revenue | $1.30M |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -9465.46% |
| Profit Margin | +0.00% |
| ROE | -354.69% |
| Current Ratio | 6.46 |
| Total Cash | $161.66M |
| Total Debt | $180.90M |
| Free Cash Flow | $-89.11M |
Source: Nexqual, July 25, 2026 at 04:58 UTC.
Financial Health Score (INBX)
Nexqual rates Inhibrx Biosciences, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 04:58 UTC.
| Growth | Strong — Revenue +550% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $162M cash vs $181M debt |
| Cash Flow | Weak — FCF negative: -$89M, burning cash |
| Efficiency | Critical — ROE -355%, ROA -36.1% |
Ownership (INBX)
| Insider Ownership | +23.16% |
|---|---|
| Institutional Ownership | +82.25% |
| Shares Outstanding | 14.67M |
| Float | 8.37M |
| Short % of Float | +31.28% |
Source: Nexqual, July 25, 2026 at 04:58 UTC.
Leadership (INBX)
Inhibrx Biosciences, Inc. is led by Mark Paul Lappe (age 58), Founder, CEO & Chairman, per Nexqual as of July 25, 2026 at 04:58 UTC.
| Founder, CEO & Chairman | Mark Paul Lappe (age 58) |
|---|---|
| President | David J. Matly (age 39) |
| Executive VP, CFO & Treasurer | Kelly Devine Deck B.S., CPA, M.S. (age 45) |
| Vice President of Operations | Bonne Adams (age 48) |
| Vice President of Accounting | Kate Burke |
Major Backers & Investors (INBX)
Notable institutional backers of Inhibrx Biosciences, Inc. include Perceptive Advisors Llc, Viking Global, Morgan Stanley, according to Nexqual as of July 25, 2026 at 04:58 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Perceptive Advisors Llc | 9.83% |
| Viking Global | 9.8% |
| Morgan Stanley | 8.61% |
| Sanofi | 7.89% |
| HighTower Advisors, LLC | 5.93% |
| Sofinnova Investments, Inc. | 2.77% |
| Capital Group | 2.68% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.98% |
| Vanguard Group | 6.54% |
| State Street | 6.47% |
Source: Nexqual, July 25, 2026 at 04:58 UTC.
From Inhibrx Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Overview We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms.
- Our Solution — ozekibart Ozekibart is a tetravalent agonist of DR5 that we designed with our proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis.
- We have engineered ozekibart with our proprietary sdAb modifications to reduce recognition by pre-existing anti-drug antibodies in humans, which can lessen the potential for hyper-clustering and thereby reduce potential hepatotoxicity. 6 ozekibart: Tetravalent DR5 Agonistic Antibody Phase 1/2 Clinical Trial of ozekibart We initiated a Phase 1 clinical trial in the United States in November 2018.
- Intellectual Property We strive to protect the proprietary technology and information commercially or strategically important to our business.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | USD 10.06 | ▼ 1.47% |
| KYMR | Kymera Therapeutics, Inc. | USD 110.57 | ▲ 0.21% |
| FDMT | 4D Molecular Therapeutics, Inc. | USD 10.07 | ▼ 8.12% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | USD 4.33 | ▼ 3.78% |
| PCVX | Vaxcyte, Inc. | USD 54.66 | ▼ 2.39% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:58 UTC. This page is informational and not investment advice.